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Disclosing Risks of New Technologies: Ethical 
Challenges for Physicians, Patients, and Companies 
Dianne M. Bartels* 
I. INTRODUCTION 
The number of patient deaths linked to implanted cardiac 
defibrillators (ICDs) underscores the importance of balancing 
patient autonomy and risk disclosure, and raises a number of 
questions for both clinicians and medical device manufacturers.  
At what level of risk of death should patients be notified?  What 
information should be provided to the patient prior to gaining 
consent for initiation of new therapies?  Is there an ongoing 
responsibility to disclose new risk information?  What do 
doctors need to know to meet their obligations?  What role 
should manufacturers play in risk notification?  I will attempt 
to answer these questions from a clinical practice perspective 
with a particular focus on obligations to patients faced with 
difficult medical decisions. 
Questions about risk disclosure have not been definitively 
answered even for clinical trials.1  However, ethical guidance 
developed for researchers could shed light on the physician’s 
responsibilities related to risk notification, particularly where 
risks are life-threatening. 
II. PHYSICIAN’S DUTY TO DISCLOSE RISKS AND 
BENEFITS 
The Belmont Report describes an obligation to inform 
research participants of risks and benefits based on the 
principle of respecting individual autonomy.2  Informed consent 
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was developed to protect participants from undergoing undue 
risks.  The duty for physicians to disclose risks and benefits as 
a part of consent to participate was defined as an expectation 
that would allow participants to determine, within the context 
of their own value system, whether to become part of a study.  
In The Belmont Report, failure to notify participants about 
relevant risks was described as tantamount to showing 
disrespect: “To show lack of respect for an autonomous agent is 
to repudiate that person’s considered judgments, to deny an 
individual the freedom to act on those considered judgments, or 
to withhold information necessary to make a considered 
judgment, when there is no compelling reason to do so.”3 
III. RESPECT FOR AUTONOMY IN CLINICAL PRACTICE 
The principles that originally guided the conduct of 
research have become guiding principles for decisions about 
medical treatment as well.  Consent was a major mechanism in 
the evolution of medical practice from paternalism, where 
doctors acted in the best interest of patients, to respect for 
autonomy, which supports patients’ personal well-being and 
self-determination.  Ideally, consent is a collaborative process 
in which the physician shares information about risks and 
benefits and patients determine where an intervention fits in 
the context of their own lives. 
So, where does risk notification fit into informed consent?  
“Risk” refers to an adverse future event that is not certain, but 
probable.4  The duty to warn patients of risks of a proposed 
treatment is a facet of due care.5  The patient’s right to self-
determination shapes the boundaries of the physician’s duty to 
reveal risks.6  In that context, a physician’s communication is 
measured by a patient’s need to know information that is 
material to a specific medical decision.7  A risk is material 
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when a reasonable person would be likely to attach significance 
to the risk in deciding whether or not to forego the proposed 
therapy.8  Because life-preservation is the purpose of new 
cardiac technologies, a risk of death would seem material to 
every patient offered ICD treatment.  Therefore, one might say 
that if sudden death is even a miniscule risk, the patient 
should be apprised of that risk. 
Of course there are challenges to total disclosure.  First, it 
is impossible to cover all potential risks of any technology in 
relation to a specific individual’s physiological response or 
unique value system.  Therefore, physicians must select 
information that is relevant for each patient.9  Second, volumes 
have been written about the challenges in conveying 
probabilities in a way that is meaningful to a particular 
individual.  Uncertainty about the likelihood of failure in an 
individual situation compounds that challenge.  Third, if an 
emergency decision must be made in the context of a life-
threatening event, the obligation to disclose may be set aside in 
order to save the patient from undue harm.10  Fourth, some 
patients do not want to hear about risks and ask that someone, 
in some cases their doctors, make decisions about what would 
be best for them.  Finally, clinical practice has also shown that 
many patient decisions do not seem rational in terms of 
statistical risks.  For instance, some people have ICDs removed 
because experiencing the electrical shocks is more worrisome 
than the risk of death without the defibrillator.  Also, some 
patients, with their families, decide that survival is not their 
most important goal when the quality of their lives is severely 
diminished.  Despite these challenges to “rational” 
decisionmaking, the physician’s responsibility continues to be 
one of sharing information about the risks and benefits of each 
medical intervention proposed. 
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IV. COMPARING CONSENT IN CLINICAL TRIALS TO 
CONSENT IN TREATMENT 
Many risks present in a clinical trial continue to be risks 
when an innovative technology has been approved for use as a 
medical treatment.  Surprisingly, one often finds in a patient’s 
medical record great disparity between the consent process 
during research and treatment phases.  Consent to be involved 
in research usually involves a form of ten to twenty (or more) 
pages listing every possible risk: physical risks, psychological 
risks, commentary on lifestyle considerations, as well as the 
risks and consequences of technical malfunction.  Once an 
intervention is approved for treatment, however, we often find 
a routine surgical consent in the patient’s medical record, often 
with a very non-specific note from a physician indicating that 
the patient understands the risks and benefits of the proposed 
intervention.   
Given the enormous discrepancy between consent in 
clinical trials and consent once approval for treatment is 
obtained, I would advocate for a more specific written consent 
process for new cardiac technologies.  Each of the risks 
identified in a clinical trial could be reevaluated with trial data, 
and a consent form created to include actual known risks.  
Katrina Bramstedt, a former fellow in the Program in 
Biomedical and Research Ethics at the University of 
California–Los Angeles, has suggested that consent in clinical 
trials be maintained as a “living” document.11  Likewise, 
consent forms for treatment would need to be continually 
updated to reflect the accrual of new risk data. 
Physicians would still need to consider the individual 
patient to determine what risk information is most relevant for 
their conversation.  They would also need to continue to 
evaluate the ability of the patient to understand and handle 
various levels of information and to make decisions.  Patients 
eligible for treatment with ICDs are in a unique situation 
because they risk death with or without treatment.  Therefore, 
a conversation about risks would in most cases address relative 
risk: How the risk of failure of a particular device compares 
with the risk of death without the intervention. 
What about the responsibility of the physician to contact 
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patients when a higher risk is determined or when a recall is 
announced?  It seems that new risks would be material to many 
patients and that a physician who knows an individual 
patient—and the patient’s interest in knowing about risks—
should determine when and how patients should be notified. 
One Minnesota mother decided, after a device recall, to 
take her son back to surgery to replace an ICD with an ICD 
produced by another company.12  As patients and families are 
deciding about replacing one device with another, device failure 
risks could be compared, factoring in the additional mortality 
risk of an added surgical procedure.  Patient care has become 
an onerous responsibility in the age of new technological 
interventions, and the burden for physicians treating patients 
with innovative therapies has become heavier.  Although it is 
challenging, I believe the physician responsible for initiating a 
particular therapy remains the best person to discuss relative 
risks over time. 
V. ROLE OF MANUFACTURERS TO SHARE INFORMATION 
Given that the physician needs to share all relevant 
information with patients, physicians should definitely be 
apprised of known risks and a revised likelihood of a death-
inducing malfunction.  It might be useful to provide physicians 
with information similar to that disclosed in the failure mode 
and effects analysis (FMEA), which is supplied to the FDA as a 
means of determining clinical risks.13  Information for 
physicians would also need to be updated as post-trial 
assessment reveals new risks or new probability of risk.  The 
physician would then need to decide whether to contact 
patients to warn them of a risk of death and to discuss 
treatment options available.  Because “first do no harm” is not 
possible, the next best step is acknowledging potential harms 
as honestly as possible during both research and treatment 
phases of new product trial and dissemination. 
Some suggest direct notification of patients by 
manufacturers, similar to that of auto vehicle recalls.14  My 
sense is that increased risk and recall information should be 
given to physicians, who would then determine how such 
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information should be given to individual patients based on 
what the physician knows about the patient’s health, lifespan, 
risk averseness, and other factors.  To support the physician’s 
capability, a company could maintain a website that regularly 
posts current data about the likelihood of varying risks.15  That 
site could be made available to interested patients, the public, 
and to physicians who could share revised estimates as a part 
of the consent and continuing treatment process. 
No system of notification is perfect.  Hopefully, the 
challenges coming from these well-publicized “worst case” 
scenarios will lead to an industry standard of full and 
continuing disclosure.  Otherwise companies acting ethically to 
disclose relevant risks may be disadvantaged in the 
marketplace. 
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